Introduction
Chongkukjang is a fermented product manufactured by shortterm fermentation of soybean using Bacillus subtilis that contains many microorganisms and bioactive compounds that are absent from unfermented soybeans ( Fig. 1) [1e3]. Flavonoid glycosides are converted into aglycones by hydrolysis during fermentation of Chongkukjang, and many of the proteins are degraded into small peptides and amino acids [4] . Koreans have been consuming Chongkukjang for hundreds of years, and most believe that Chongkukjang consists of proteins and minerals that promote the generation and growth of human cells and strengthen the immune system [5, 6] . Chongkukjang has multiple functions, including antidiabetic, antiinflammatory, and neuroprotective effects [5, 7] .
Influenza viruses are respiratory pathogens that affect humans and are responsible for substantial morbidity, mortality, and decreased productivity worldwide [8] . Influenza viruses contain two glycoproteins on their surface, hemagglutinin (HA) and neuraminidase (NA), which recognize sialic acid in hostecell glycoconjugates. HA binds to terminal sialic acid groups on cell surface glycoconjugates, leading to attachment and subsequent penetration of virus into cells, and NA exhibits enzymatic activity that removes sialic acid from glycoconjugates, facilitating the release of progeny virions from infected cells and preventing the aggregation of progeny virions [9] . Neuraminidase inhibitors (NAIs) act by binding to the active site of the viral NA enzyme and preventing release and spread of progeny virions from infected cells during the replication cycle [10] . NAIs block the neuraminidase active site and prevent release and spread of new virions [11] . NA was chosen as a suitable drug target because it plays a major role in the propagation of influenza viruses, and the amino acid residues of the active site interacting directly with the substrate or surrounding the central active site of the enzyme are strictly conserved [12] . Treating influenza with NAIs has become the most popular treatment among primary care doctors. NAIs were introduced to clinical practice in 1999, but so far only zanamivir and oseltamivir have been licensed for use in humans [13] . Unfortunately, viruses resistant to zanamivir and oseltamivir have been generated in vitro and in humans recently [14] . This highlights the urgent need for new and readily available antiinfluenza agents. In the present study, we investigated the antiinfluenza activities of Chongkukjang extracts and demonstrated their efficacy.
Materials and methods

Viruses
The influenza virus used in this study (Influenza A/NWS/33; Influenza A/chicken/Korea/MS96/96) was propagated in the allantoic sac of 10-day-old specific pathogen-free embryonated eggs. These virus stocks were frozen at À80 C until use. Viral HA units were determined in 96-well microtiter plates using 1% chicken red blood cells.
Fluorometric neuraminidase activity assay
A fluorescence-based NA inhibition assay was used to determine the sensitivity of the viruses to NAIs. The assay is based on the release of a 4-methylumbelliferone fluorescent product from the 2-(4-methylumbelliferyl)-a-d-N-acetylneuraminic acid (MUNANA) substrate (Sigma, St. Louis, MO, USA) as a measure of NA activity. The NA activity assay was carried out to determine the dilution of each virus to be used in the subsequent NA inhibition assay. Twofold dilutions of virus in assay buffer (32.5mM MES [2-(N-morpholino)ethanesulfonic acid], pH 6.5, 4mM CaCl 2 with 0.1% NP-40, and 0.3 mg/mL bovine serum albumin) were prepared, mixed with an equal volume (50 mL) of MUNANA substrate (0.3mM), and incubated at 37 C for 60 minutes. The reaction was terminated by adding 100 mL stop solution (0.14M NaOH in 83% ethanol). The fluorometric quantification of 4-methylumbelliferone was determined using a VICTOR X4 Multilabel Plate Reader (Perki-nElmer Inc., Waltham, MA, USA) at an excitation wavelength of 360 nm and an emission wavelength of 448 nm. The appropriate concentration of virus for use in the NA inhibition assay was determined by selecting a dilution of virus in the linear portion of the enzyme activity curve. Zanamivir was obtained from Sigma and used as a positive control.
This assay was performed in duplicate for each isolate, and the half-maximal inhibitory concentration (IC 50 ) value for each virus and for each antiviral agent was determined. The IC 50 is the antiviral agent concentration that inhibits 50% of neuraminidase activity.
Isolation of an active component from Chongkukjang
Commercial Chongkukjang samples were obtained from Sunchang MoonOkrae Food (Sunchang, Korea), and the extracts were prepared by the Korea Food Research Institute. Briefly, Chongkukjang was extracted with ethanol, and the liquid was removed by evaporation. The residue was suspended and successively partitioned in fractions of ethyl acetate, butanol, and water. The total crude extract was dissolved in CH 2 Cl 2 /H 2 O (95:5), and the ethyl acetate fraction was subjected to silica open-column chromatography. The mobile phase solvent was dichloromethane/ethanol diluted as 95:5, 90:10, 80:20, and 50:50. All 10 subfractions were combined (A1eA10) based on thin-layer chromatography analysis.
Animal model and experimental design
Female (weight, 17e19 g) 6-week-old specific pathogen-free BALB/c mice (Daejeon, Chungnam, Korea) were used. The mice were quarantined 24 hours prior to use. The AIN-93M diet was provided as feed throughout the experiment, as recommended by the American Institute of Nutrition [15] . All animals received humane care in compliance with the National Association of Laboratory Animal Care and were fed in isolation (Three-Shine, Daejeon, Korea).
To investigate the safety of the Chongkukjang extract in mice, the mice were administered the ethyl acetate, A3, and A8 fractions, as well as genistein (0.4 g/kg/d of body weight). Phosphatebuffered saline was given to the normal control group. The mice were divided into groups of 10 each, and the treatments were carried out for 14 days. Clinical signs were recorded daily, and the body weight was measured on Days 0, 7, 10, and 14.
To investigate the protective activity of the Chongkukjang extracts against lethal influenza virus in vivo, the mice were divided into groups of 10 each. The inoculated mice received the ethyl acetate, A3, and A8 extracts as well as genistein (0.2 and 0.4 g/kg/d), respectively. The treatments were administered daily via gavages for 6 days before challenge and 14 days after influenza A virus challenge. Studies with mice were performed as described previously, and phosphate-buffered saline was used as the negative control. The mice were anesthetized with diethyl ether and exposed to 0.1 mL virus by intranasal instillation. A viral challenge dose of 10 7.0 50% embryo infectious dose (EID 50 )/0.1 mL (A/NWS/ 33), which was approximately 80e90% of the lethal dose, was used. Mice were observed daily for 14 days after infection. The protective effect was estimated by preventing death and prolonging the median time to death (MTD).
Data analysis
Data are expressed as the mean ± standard deviation of at least three independent experiments. Body weight was analyzed with one-way analysis of variance [16] . Statistical analyses were performed using the SPSS software (SPSS Inc., Chicago, IL, USA). A p value <0.05 was considered statistically significant.
Results
Inhibitory effect of the Chongkukjang extracts on influenza virus in vitro
The standard soybean isoflavones, such as daidzin, daidzein, genistin, genistein, glycitin, and glycitein (Sigma), were applied to the fluorometric NA activity assay, and genistein showed the best NA inhibitory effect compared with that of the five other standard soybean isoflavones (data not shown). Thus, genistein was used to control the extract composition of the Chongkukjang eluent at each step.
NA is one of the most important targets to screen antiinfluenza virus A drugs. We first investigated whether the Chongkukjang fractions exerted antiviral action. The ethyl acetate, butanol, and water fractions were measured using the fluorometric NA activity assay. The ethyl acetate fraction showed the best NA inhibitory effect compared with that of butanol and water (data not shown). Thus, the ethyl acetate fraction was used for further purification. The Chongkukjang extracts were dose-dependently effective against influenza A virus, and the calculated IC 50 values of the extracts against the influenza virus are shown in Table 1 . The A3 extract showed the best NA inhibitory effect against influenza A virus. The A8 extract also showed a high inhibitory effect. The Chongkukjang extract seemed to be more effective against A/NWS/ 33 (H1N1) than against A/chicken/Korea/MS96/9 (H9N2). Genistein showed similar effects against A/NWS/33 (H1N1) and A/chicken/ Korea/MS96/96 (H9N2).
Inhibitory effect of the Chongkukjang extracts on the influenza virus in vivo
We next tested whether the Chongkukjang extract, which inhibited NA activity, could relieve a viral infection in vivo. First, we assessed the safety of the Chongkukjang extract in mice. Animals treated with the Chongkukjang extract maintained a relatively steady weight, and mean body weights of the treated mice, except the A8 group, were higher than those of the control group, but no significant differences were observed throughout the study ( Table 2 ). No clinical symptoms were observed throughout the study.
To investigate the protective effect of the Chongkukjang extract in vivo, groups of mice were inoculated with 10 7.0 EID 50 /0.1 mL A/ NWS/33 (H1N1). All of the mice that received the ethyl acetate, A3, and A8 extracts as well as genistein (0.4 g/kg/d) died within the experimental period (data not shown). The results for mice that received a dose of 0.2 g/kg/d are shown in Fig. 2 . About 10% of the mice from the positive control group survived until the end of the experiment. All challenge groups, except the genistein group (0.2 g/ kg) and the A3 group (0.2 g/kg), died by 8 days after infection. The MTD of the mice treated with the A3 and A8 (0.2 g/kg) extracts was 5 and 6 days, which was longer than that of the viral control group (3 days). The survival rate in the A3 group (0.2 g/kg) at 14 days post infection was 20%, which was higher than that of the viral control group (10%).
Discussion
There is an urgent medical need to develop new strategies against influenza virus infection. At the moment antiviral drugs are the only known defense against the disease, as no vaccine is available, which is similar to the early phase of a pandemic or when the prediction for the seasonal influenza vaccine composition fails. In 2010, the World Health Organization suggested the development of novel and effective treatment strategies for influenza virus including natural products [17] . This prompted us to investigate the antiviral activity of traditional food extracts against influenza virus infection. The goal of this study was to determine whether Chongkukjang extracts could function as an antiviral agent against influenza A virus, because Chongkukjang has a strong record in the literature for its beneficial effects on human health [12, 18] . Our results suggest for the first time that the Chongkukjang extracts were active against the influenza A virus.
Influenza virus NA is thought to be required to secrete newly synthesized virus from infected cells and to aid in the movement of the virus. NA can be administered relatively late in the viral infection and still render a significant antiviral effect [19] . Genistein showed a better effect than the A3 and A8 extracts against A/NWS/ 33 (H1N1) and A/chicken/Korea/MS96/96 (H9N2), suggesting that other active compounds may be present within this extract. This result agreed with those for the ethyl acetate fraction, which showed less efficiency than the further purified A3 and A8 extracts. Although the Chongkukjang extracts showed less activity than zanamivir and oseltamivir, Chongkukjang extracts showed possible research directions as a potential candidate for zanamivir-and oseltamivir-resistant cases in clinical practice. This provides a good backdrop considering that after 3 years of NAI use, it has been noted that 0.35% of isolates were found to have become resistantdin particular, higher percentages of such resistance have been observed in children [20, 21] .
Wide variations in the IC 50 for oseltamivir are observed in seasonal influenza A with or without the virus subtype [22] . Genistein has a weak NA inhibitory effect of about 20 mg/mL IC 50 against the H1N1 influenza A virus [23] . Our result showed about six times higher efficiency of the IC 50 against the same NA type of influenza A virus. An NA gene mutation (H274Y, H275Y in N1 numbering) has been associated with NA inhibitor susceptibility [24] . The Chongkukjang extracts showed a better inhibitory effect against A/ NWS/33 (H1N1) than that against A/chicken/Korea/MS96/96 (H9N2). This result agrees with the finding that avian isolates have significantly higher resistance to NAIs than that of human isolates [25] . It is not apparent how accurately the IC 50 values determined from the enzyme inhibition assay results reflect actual differences in inhibitor potency. Once efficacy is observed against an influenza virus, it is important to use a variety of other virus strains in followup evaluations to ascertain if the antiviral effect applies to all viral strains encountered in the clinic. As the Chongkukjang extracts showed antiviral effects in vitro, a mouse study was performed to determine the in vivo effects of the Chongkukjang extracts against influenza A virus. Treatment with the A3 and A8 (0.2 g/kg) extracts produced a modest inhibitory effect on influenza A virus replication in mice. Influenza virusinfected mice receiving the Chongkukjang extract treatment did not show reduced mortality, but the A3 and A8 extracts delayed the mice MTD after influenza A virus infection. This result shows that the Chongkukjang extract is a potential candidate to fight influenza A virus infection. The Chongkukjang-treated groups (except the A8 group) maintained a higher body weight compared with the control group, which agrees with previous reports that soybean-related products increase body weight and lower the risk of toxic side effects at a low concentration [14, 26] . This extract may be a potent antiviral agent against influenza virus with no host toxicity.
We found that the A3 and A8 Chongkukjang extracts had a potential inhibitory activity against influenza viruses. This study is another example showing how plant extracts are capable of inhibiting influenza A virus infection. This study addresses the latest developments in theoretical and experimental research on the properties of NA that are and will be driving antiinfluenza drug development today and in the near future. Two further research directions can be undertaken. One would be to further characterize and identify the antiviral compounds in the extracts. Nevertheless, it is also important to determine whether only one compound, several closely related compounds, or the composite activity of several different molecules is/are responsible for the observed antiviral activity and whether the activity is selective for influenza viruses. We clearly need to focus more attention on ethnic foods, not only for nutrition but also for the functionality they provide in disease control.
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